David Pauling Biography and Net Worth

Insider of Sutro Biopharma

David Pauling, J.D., M.A., has served as Chief Administrative Officer and General Counsel of Sutro since April 2025. He joined Sutro in 2011 and, prior to his appointment to his current role, held positions of increasing responsibility across the Company, including Intellectual Property Counsel, Associate General Counsel and Senior Intellectual Property Counsel, and Executive Director of Legal Affairs, and General Counsel.

Prior to Sutro, David practiced law at Jones Day and at Pennie & Edmonds, LLP. He received his J.D. from Santa Clara University School of Law (magna cum laude), and an M.A. in Molecular Biology and a B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz.

What is David Pauling's net worth?: The estimated net worth of David Pauling is at least $246.39 thousand as of October 15th, 2025. Mr. Pauling owns 7,173 shares of Sutro Biopharma stock worth more than $246,393 as of April 21st. This net worth evaluation does not reflect any other investments that Mr. Pauling may own. Learn More about David Pauling's net worth.
How do I contact David Pauling?: The corporate mailing address for Mr. Pauling and other Sutro Biopharma executives is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. Sutro Biopharma can also be reached via phone at (650) 392-8412 and via email at [email protected]. Learn More on David Pauling's contact information.
Has David Pauling been buying or selling shares of Sutro Biopharma?: David Pauling has not been actively trading shares of Sutro Biopharma during the last quarter. Most recently, on Wednesday, October 15th, David Pauling bought 1,250 shares of Sutro Biopharma stock. The stock was acquired at an average cost of $8.00 per share, with a total value of $10,000.00. Following the completion of the transaction, the insider now directly owns 7,173 shares of the company's stock, valued at $57,384. Learn More on David Pauling's trading history.
Who are Sutro Biopharma's active insiders?: Sutro Biopharma's insider roster includes Connie Matsui (Director), David Pauling (Insider), and Nicki Vasquez (Insider). Learn More on Sutro Biopharma's active insiders.
Are insiders buying or selling shares of Sutro Biopharma?: During the last year, Sutro Biopharma insiders bought shares 5 times. They purchased a total of 11,175 shares worth more than $89,597.50. The most recent insider tranaction occured on October, 15th when insider Hans-Peter Gerber bought 1,700 shares worth more than $13,600.00. Insiders at Sutro Biopharma own 5.9% of the company. Learn More about insider trades at Sutro Biopharma.
Information on this page was last updated on 10/15/2025.

David Pauling Insider Trading History at Sutro Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/15/2025	Buy	1,250	$8.00	$10,000.00	7,173

David Pauling Buying and Selling Activity at Sutro Biopharma

Sutro Biopharma Company Overview

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Today's Range

Now: $34.35

$33.61

$35.40

50 Day Range

MA: $22.82

$15.62

$34.58

2 Week Range

Now: $34.35

$5.60

$35.40

Volume

192,597 shs

Average Volume

173,493 shs

Market Capitalization

$569.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31